Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus

what is the clinical relevance?

Steven Tong, Luke Chen, Vance Fowler Jr

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Staphylococcus aureus is a human commensal that can also cause a broad spectrum of clinical disease. Factors associated with clinical disease are myriad and dynamic and include pathogen virulence, antimicrobial resistance, and host susceptibility. Additionally, infection control measures aimed at the environmental niches of S. aureus and therapeutic advances continue to impact upon the incidence and outcomes of staphylococcal infections. This review article focuses on the clinical relevance of advances in our understanding of staphylococcal colonization, virulence, host susceptibility, and therapeutics. Over the past decade key developments have arisen. First, rates of nosocomial methicillin-resistant S. aureus (MRSA) infections have significantly declined in many countries. Second, we have made great strides in our understanding of the molecular pathogenesis of S. aureus in general and community-associated MRSA in particular. Third, host risk factors for invasive staphylococcal infections, such as advancing age, increasing numbers of invasive medical interventions, and a growing proportion of patients with healthcare contact, remain dynamic. Finally, several new antimicrobial agents active against MRSA have become available for clinical use. Humans and S. aureus co-exist, and the dynamic interface between host, pathogen, and our attempts to influence these interactions will continue to rapidly change. Although progress has been made in the past decade, we are likely to face further surprises such as the recent waves of community-associated MRSA.
Original languageEnglish
Pages (from-to)185-200
Number of pages16
JournalSeminars in Immunopathology
Volume34
Issue number2
DOIs
Publication statusPublished - 2011

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Virulence
Staphylococcus aureus
Staphylococcal Infections
Therapeutics
Infection Control
Anti-Infective Agents
Delivery of Health Care
Incidence
Infection

Cite this

@article{3f81d37868cb41c7aa1a09fd26ba8879,
title = "Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?",
abstract = "Staphylococcus aureus is a human commensal that can also cause a broad spectrum of clinical disease. Factors associated with clinical disease are myriad and dynamic and include pathogen virulence, antimicrobial resistance, and host susceptibility. Additionally, infection control measures aimed at the environmental niches of S. aureus and therapeutic advances continue to impact upon the incidence and outcomes of staphylococcal infections. This review article focuses on the clinical relevance of advances in our understanding of staphylococcal colonization, virulence, host susceptibility, and therapeutics. Over the past decade key developments have arisen. First, rates of nosocomial methicillin-resistant S. aureus (MRSA) infections have significantly declined in many countries. Second, we have made great strides in our understanding of the molecular pathogenesis of S. aureus in general and community-associated MRSA in particular. Third, host risk factors for invasive staphylococcal infections, such as advancing age, increasing numbers of invasive medical interventions, and a growing proportion of patients with healthcare contact, remain dynamic. Finally, several new antimicrobial agents active against MRSA have become available for clinical use. Humans and S. aureus co-exist, and the dynamic interface between host, pathogen, and our attempts to influence these interactions will continue to rapidly change. Although progress has been made in the past decade, we are likely to face further surprises such as the recent waves of community-associated MRSA.",
keywords = "altastaph, antiinfective agent, aurograb, aztreonam, bacterial protein, bacterial vaccine, beta lactam antibiotic, ceftaroline, daptomycin, immunoglobulin, inh a21, linezolid, monoclonal antibody, pagibaximab, Panton Valentine leukocidin, penicillin G, polypeptide antibiotic agent, Staphylococcus vaccine, staphyloxanthin, telavancin, tigecycline, unclassified drug, v 710, vancomycin, veronate, abdominal infection, antibiotic resistance, bacteremia, bacterial colonization, bacterial virulence, clinical feature, community acquired pneumonia, comorbidity, disease association, disorders of mitochondrial functions, drug blood level, drug cost, drug distribution, drug efficacy, drug safety, endocarditis, gastrointestinal symptom, genotype, hospital acquired pneumonia, host susceptibility, human, immune deficiency, infection risk, kidney failure, lactic acidosis, methicillin resistant Staphylococcus aureus infection, nausea, neuropathy, nonhuman, pneumonia, priority journal, review, skin infection, skin protection, staphylococcal skin infection, Staphylococcus aureus, Staphylococcus infection, thrombocytopenia, unspecified side effect, vomiting, Disease Susceptibility, Environment, Host-Pathogen Interactions, Humans, Methicillin-Resistant Staphylococcus aureus, Risk Factors, Staphylococcal Infections",
author = "Steven Tong and Luke Chen and {Fowler Jr}, Vance",
year = "2011",
doi = "10.1007/s00281-011-0300-x",
language = "English",
volume = "34",
pages = "185--200",
journal = "Seminars in Immunopathology",
issn = "1863-2297",
publisher = "Springer",
number = "2",

}

Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus : what is the clinical relevance? / Tong, Steven; Chen, Luke; Fowler Jr, Vance.

In: Seminars in Immunopathology, Vol. 34, No. 2, 2011, p. 185-200.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus

T2 - what is the clinical relevance?

AU - Tong, Steven

AU - Chen, Luke

AU - Fowler Jr, Vance

PY - 2011

Y1 - 2011

N2 - Staphylococcus aureus is a human commensal that can also cause a broad spectrum of clinical disease. Factors associated with clinical disease are myriad and dynamic and include pathogen virulence, antimicrobial resistance, and host susceptibility. Additionally, infection control measures aimed at the environmental niches of S. aureus and therapeutic advances continue to impact upon the incidence and outcomes of staphylococcal infections. This review article focuses on the clinical relevance of advances in our understanding of staphylococcal colonization, virulence, host susceptibility, and therapeutics. Over the past decade key developments have arisen. First, rates of nosocomial methicillin-resistant S. aureus (MRSA) infections have significantly declined in many countries. Second, we have made great strides in our understanding of the molecular pathogenesis of S. aureus in general and community-associated MRSA in particular. Third, host risk factors for invasive staphylococcal infections, such as advancing age, increasing numbers of invasive medical interventions, and a growing proportion of patients with healthcare contact, remain dynamic. Finally, several new antimicrobial agents active against MRSA have become available for clinical use. Humans and S. aureus co-exist, and the dynamic interface between host, pathogen, and our attempts to influence these interactions will continue to rapidly change. Although progress has been made in the past decade, we are likely to face further surprises such as the recent waves of community-associated MRSA.

AB - Staphylococcus aureus is a human commensal that can also cause a broad spectrum of clinical disease. Factors associated with clinical disease are myriad and dynamic and include pathogen virulence, antimicrobial resistance, and host susceptibility. Additionally, infection control measures aimed at the environmental niches of S. aureus and therapeutic advances continue to impact upon the incidence and outcomes of staphylococcal infections. This review article focuses on the clinical relevance of advances in our understanding of staphylococcal colonization, virulence, host susceptibility, and therapeutics. Over the past decade key developments have arisen. First, rates of nosocomial methicillin-resistant S. aureus (MRSA) infections have significantly declined in many countries. Second, we have made great strides in our understanding of the molecular pathogenesis of S. aureus in general and community-associated MRSA in particular. Third, host risk factors for invasive staphylococcal infections, such as advancing age, increasing numbers of invasive medical interventions, and a growing proportion of patients with healthcare contact, remain dynamic. Finally, several new antimicrobial agents active against MRSA have become available for clinical use. Humans and S. aureus co-exist, and the dynamic interface between host, pathogen, and our attempts to influence these interactions will continue to rapidly change. Although progress has been made in the past decade, we are likely to face further surprises such as the recent waves of community-associated MRSA.

KW - altastaph

KW - antiinfective agent

KW - aurograb

KW - aztreonam

KW - bacterial protein

KW - bacterial vaccine

KW - beta lactam antibiotic

KW - ceftaroline

KW - daptomycin

KW - immunoglobulin

KW - inh a21

KW - linezolid

KW - monoclonal antibody

KW - pagibaximab

KW - Panton Valentine leukocidin

KW - penicillin G

KW - polypeptide antibiotic agent

KW - Staphylococcus vaccine

KW - staphyloxanthin

KW - telavancin

KW - tigecycline

KW - unclassified drug

KW - v 710

KW - vancomycin

KW - veronate

KW - abdominal infection

KW - antibiotic resistance

KW - bacteremia

KW - bacterial colonization

KW - bacterial virulence

KW - clinical feature

KW - community acquired pneumonia

KW - comorbidity

KW - disease association

KW - disorders of mitochondrial functions

KW - drug blood level

KW - drug cost

KW - drug distribution

KW - drug efficacy

KW - drug safety

KW - endocarditis

KW - gastrointestinal symptom

KW - genotype

KW - hospital acquired pneumonia

KW - host susceptibility

KW - human

KW - immune deficiency

KW - infection risk

KW - kidney failure

KW - lactic acidosis

KW - methicillin resistant Staphylococcus aureus infection

KW - nausea

KW - neuropathy

KW - nonhuman

KW - pneumonia

KW - priority journal

KW - review

KW - skin infection

KW - skin protection

KW - staphylococcal skin infection

KW - Staphylococcus aureus

KW - Staphylococcus infection

KW - thrombocytopenia

KW - unspecified side effect

KW - vomiting

KW - Disease Susceptibility

KW - Environment

KW - Host-Pathogen Interactions

KW - Humans

KW - Methicillin-Resistant Staphylococcus aureus

KW - Risk Factors

KW - Staphylococcal Infections

UR - http://www.scopus.com/inward/record.url?scp=84859845115&partnerID=8YFLogxK

U2 - 10.1007/s00281-011-0300-x

DO - 10.1007/s00281-011-0300-x

M3 - Article

VL - 34

SP - 185

EP - 200

JO - Seminars in Immunopathology

JF - Seminars in Immunopathology

SN - 1863-2297

IS - 2

ER -